Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Enveric Biosciences Inc (NQ: ENVB ) 0.5176 UNCHANGED Streaming Delayed Price Updated: 12:57 PM EDT, Jul 3, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Enveric Biosciences Inc < Previous 1 2 3 Next > Enveric Biosciences Files Provisional Patent Application for AI-based Computational Methods for Identifying and Optimizing Novel Tryptamine Derivatives September 11, 2023 From Enveric Biosciences Via Business Wire Enveric Biosciences Announces New U.S. Patent for C4-Carboxylic Acid-Substituted Tryptamine Derivatives September 05, 2023 From Enveric Biosciences Via Business Wire Enveric Biosciences to Present at H.C. Wainwright 25th Annual Global Conference August 30, 2023 From Enveric Biosciences Via Business Wire Enveric Biosciences Inc. (NASDAQ: ENVB) Leading the Way in Wednesday Trading Based on Percentage Gain May 24, 2023 Via Investor Brand Network Enveric Biosciences Strengthens Intellectual Property Portfolio with New U.S. Patent for Tryptamine-derived Prodrugs August 28, 2023 From Enveric Biosciences Via Business Wire Enveric Biosciences Completes Manufacturing of EB-373 to Supply Drug Material for Completion of Preclinical Program August 21, 2023 From Enveric Biosciences Via Business Wire Enveric Biosciences Reports Second Quarter 2023 Corporate and Financial Results August 14, 2023 From Enveric Biosciences, Inc. Via Business Wire Enveric Biosciences Reports Positive Results from Preclinical Studies Supporting Metabolic Profile of Lead Candidate EB-373 July 24, 2023 From Enveric Biosciences Via Business Wire Enveric Biosciences Reports Positive Results from Animal Studies Demonstrating Oral Bioavailability and Well Tolerated Side Effect Profile for EB-373 July 17, 2023 From Enveric Biosciences Via Business Wire Enveric Biosciences Announces Development of Phase 1-Ready Formulation for EB-373 and Initiation of Scaled Up Manufacturing June 26, 2023 From Enveric Biosciences Via Business Wire Enveric Biosciences to Present at H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference June 12, 2023 From Enveric Biosciences Via Business Wire Enveric Biosciences Announces Two Poster Presentations at the Canadian Chemistry Conference and Exhibition (CSC 2023) June 07, 2023 From Enveric Biosciences, Inc. Via Business Wire Enveric Biosciences Receives Notice of Allowance from USPTO for EVM301 Series of Drug Candidates June 05, 2023 From Enveric Biosciences, Inc. Via Business Wire Enveric Biosciences Announces Poster Presentation at Canadian Neuroscience Meeting 2023 May 30, 2023 From Enveric Biosciences, Inc. Via Business Wire Enveric Biosciences Receives Notice of Allowance From USPTO for C4-Carboxylic Acid-Substituted Tryptamine Derivatives for Next Generation Psilocin Prodrug May 24, 2023 From Enveric Biosciences, Inc. Via Business Wire Enveric Biosciences Announces Manuscript Detailing the Development of Novel Psilocin Prodrugs for the Treatment of Anxiety and Other Mental Health Disorders May 22, 2023 From Enveric Biosciences, Inc. Via Business Wire Enveric Biosciences to Participate in 2023 BIO International Convention in Boston May 19, 2023 From Enveric Biosciences, Inc. Via Business Wire Enveric Biosciences Inc. (NASDAQ: ENVB) is One of Thursday Morning’s Most Active Stocks May 18, 2023 Via Investor Brand Network Enveric Biosciences (NASDAQ: ENVB) Obtains Notice of Allowance For a U.S. Patent Covering Its Innovative Psilocin Prodrug, EB-373 May 18, 2023 Enveric Biosciences, Inc. (NASDAQ: ENVB) is engaged as a biotechnology company, which focused on the research and development of innovative Via Spotlight Growth Topics Derivatives Intellectual Property Exposures Derivatives Intellectual Property Enveric Biosciences Receives Notice of Allowance from USPTO for Novel Prodrug of Psilocin May 18, 2023 From Enveric Biosciences, Inc. Via Business Wire Enveric Biosciences Reports First Quarter 2023 Financial Results and Operational Highlights May 15, 2023 From Enveric Biosciences, Inc. Via Business Wire Enveric Biosciences Celebrates and Supports 2023 Mental Health Awareness Month May 02, 2023 From Enveric Biosciences, Inc. Via Business Wire Enveric Biosciences to Participate in Benzinga Psychedelics Capital Conference April 10, 2023 From Enveric Biosciences Via Business Wire Enveric Biosciences Reports Fourth Quarter and Year-End 2022 Corporate and Financial Results April 03, 2023 From Enveric Biosciences, Inc. Via Business Wire Enveric Biosciences Selects Australian CRO, Avance Clinical, in Preparation for Phase 1 Study of EB-373 March 23, 2023 From Enveric Biosciences Via Business Wire Enveric Biosciences Establishes Australia-based Subsidiary to Accelerate its Lead Psilocin Prodrug Program Targeting Mental Health Indications March 21, 2023 From Enveric Biosciences Via Business Wire Enveric Biosciences Announces Bioproduction Platform Using Novel Cane Toad Enzyme for Psychedelic-Inspired Drug Discovery March 14, 2023 From Enveric Biosciences Via Business Wire Enveric Biosciences Appoints Kevin Coveney as Chief Financial Officer, and Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) February 28, 2023 From Enveric Biosciences Via Business Wire Enveric Biosciences Names Lynn Gallant Vice President, Clinical Operations, and Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) February 23, 2023 From Enveric Biosciences Via Business Wire Enveric Biosciences to Present at the Gravitas Securities Inc. 6th Annual Growth Conference February 22, 2023 From Enveric Biosciences Via Business Wire < Previous 1 2 3 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.